← All drugs
Drug · FAERS side-effect profile with label screen

Valacyclovir Hydrochloride side effects: what 70,015 FDA adverse event reports show

Valacyclovir Hydrochloride · 1,178 reaction terms · 245,959 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Who reports

70,015 reports · 69% serious · 5,662 with death outcome · 60% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Valacyclovir tablets are a deoxynucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocom.

FDA label, Indications and Usage

What it is

Valacyclovir hydrochloride, USP is the hydrochloride salt of the L ‑valyl ester of the antiviral drug acyclovir. Valacyclovir tablets, USP are for oral administration. Each film-coated tablet .

FDA label, Description section

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled adverse reaction 1Labeled (related wording) 3Likely indication confounding 6Lab value / disease marker 4Not in label — unassessed 26
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,138 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Laryngeal stenosis10465.7
53.1–81.2ROR 65.8 · calibrated p 3e-6 ✓
53.4 EB05 45.3 · IC025 +5.1
3/3 methods agree
Not in label — unassessedserious n=104 · ♀ 100% (drug 60%) · 72% consumernot reported in cached trials
Dyslalia12864.0
52.9–77.4ROR 64.1 · calibrated p 3e-6 ✓
52.3 EB05 45.2 · IC025 +5.2
3/3 methods agree
Not in label — unassessedserious n=126not reported in cached trials
Vocal cord dysfunction8258.7
46.3–74.4ROR 58.8 · calibrated p 6e-6 ✓
48.6 EB05 40.4 · IC025 +4.9
3/3 methods agree
Not in label — unassessedserious n=82 · ♀ 100% (drug 60%)not reported in cached trials
Genital herpes14130.2
25.4–35.9ROR 30.2 · calibrated p 3e-4 ✓
27.4 EB05 23.8 · IC025 +4.4
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious n=75not reported in cached trials
Ophthalmic herpes simplex5028.5
21.3–38.1ROR 28.5 · calibrated p 4e-4 ✓
25.9 EB05 20.4 · IC025 +3.9
3/3 methods agree
Likely indication confounding
shares a disease stem with the indications wording
serious n=47 · ♀ 0% (drug 60%) · 100% cliniciannot reported in cached trials
Herpes virus infection46626.2
23.8–28.8ROR 26.4 · calibrated p 5e-4 ✓
24.1 EB05 22.3 · IC025 +4.4
3/3 methods agree
Likely indication confounding
term in indications
serious n=175 · 71% consumernot reported in cached trials
Periorbital pain5421.5
16.3–28.4ROR 21.6 · calibrated p 0.002 ✓
20.0 EB05 15.9 · IC025 +3.6
3/3 methods agree
Not in label — unassessed100% consumernot reported in cached trials
Herpes simplex42821.1
19.1–23.3ROR 21.2 · calibrated p 0.002 ✓
19.7 EB05 18.2 · IC025 +4.1
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
serious n=244not reported in cached trials
Klebsiella bacteraemia5619.1
14.6–25.1ROR 19.1 · calibrated p 0.003 ✓
17.9 EB05 14.3 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=56 · ♀ 0% (drug 60%) · 100% cliniciannot reported in cached trials
Diffuse large b-cell lymphoma refractory5418.4
14.0–24.2ROR 18.4 · calibrated p 0.003 ✓
17.3 EB05 13.7 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=53 · ♀ 100% (drug 60%) · 100% cliniciannot reported in cached trials
Herpes ophthalmic7016.9
13.3–21.5ROR 16.9 · calibrated p 0.005 ✓
15.9 EB05 13.0 · IC025 +3.5
3/3 methods agree
Not in label — unassessedserious n=65not reported in cached trials
Cytokine release syndrome95615.8
14.8–16.8ROR 16.0 · calibrated p 0.005 ✓
15.0 EB05 14.2 · IC025 +3.8
3/3 methods agree
Not in label — unassessedage-adj. PRR 16.3 · serious PRR 12.5 · ♀ 37% (drug 60%) · 97% cliniciannot reported in cached trials
Post herpetic neuralgia6614.3
11.2–18.4ROR 14.4 · calibrated p 0.009 ✓
13.6 EB05 11.0 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=45not reported in cached trials
Streptococcal bacteraemia4914.3
10.7–19.0ROR 14.3 · calibrated p 0.010 ✓
13.4 EB05 10.5 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=49 · ♀ 0% (drug 60%) · 100% cliniciannot reported in cached trials
Blood immunoglobulin e increased10513.4
11.1–16.3ROR 13.5 · calibrated p 0.012 ✓
12.8 EB05 10.8 · IC025 +3.3
3/3 methods agree
Lab value / disease markerserious n=105 · ♀ 100% (drug 60%)not reported in cached trials
Bone demineralisation4513.2
9.8–17.8ROR 13.2 · calibrated p 0.013 ✓
12.4 EB05 9.5 · IC025 +3.0
3/3 methods agree
Not in label — unassessedserious n=35 · ♀ 0% (drug 60%)not reported in cached trials
Ophthalmic herpes zoster7513.1
10.4–16.5ROR 13.1 · calibrated p 0.013 ✓
12.4 EB05 10.2 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=74not reported in cached trials
Immune effector cell-associated neurotoxicity syndrome22412.4
10.8–14.2ROR 12.4 · calibrated p 0.015 ✓
11.9 EB05 10.6 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=224 · ♀ 38% (drug 60%) · 100% cliniciannot reported in cached trials
Escherichia bacteraemia9012.1
9.8–14.9ROR 12.1 · calibrated p 0.017 ✓
11.5 EB05 9.6 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=90 · 100% cliniciannot reported in cached trials
Hepatic cytolysis47212.0
10.9–13.1ROR 12.1 · calibrated p 0.017 ✓
11.5 EB05 10.7 · IC025 +3.4
3/3 methods agree
Not in label — unassessedage-adj. PRR 9.6 · serious PRR 9.6 · 100% cliniciannot reported in cached trials
Febrile bone marrow aplasia15811.7
10.0–13.7ROR 11.7 · calibrated p 0.019 ✓
11.2 EB05 9.8 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=158 · 100% cliniciannot reported in cached trials
Eyelid pain7211.5
9.1–14.6ROR 11.5 · calibrated p 0.021 ✓
10.9 EB05 8.9 · IC025 +3.0
3/3 methods agree
Not in label — unassessed♀ 81% (drug 60%) · 100% consumernot reported in cached trials
Chronic sinusitis13711.3
9.6–13.4ROR 11.3 · calibrated p 0.021 ✓
10.8 EB05 9.4 · IC025 +3.1
3/3 methods agree
Not in label — unassessedserious n=135 · ♀ 100% (drug 60%)not reported in cached trials
Oral herpes65110.3
9.6–11.2ROR 10.4 · calibrated p 0.028 ✓
10.0 EB05 9.4 · IC025 +3.2
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 9.0 · serious PRR 9.6 · ♀ 87% (drug 60%)not reported in cached trials
Febrile neutropenia2,17610.1
9.7–10.6ROR 10.4 · calibrated p 0.028 ✓
9.8 EB05 9.5 · IC025 +3.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 10.9 · serious PRR 8.2 · 93% cliniciannot reported in cached trials
Aplastic anaemia17210.1
8.7–11.8ROR 10.1 · calibrated p 0.032 ✓
9.7 EB05 8.5 · IC025 +3.0
3/3 methods agree
Labeled adverse reaction
exact term
serious n=172 · ♀ 36% (drug 60%) · 90% cliniciannot reported in cached trials
Immunoglobulins decreased449.9
7.4–13.4ROR 9.9 · calibrated p 0.037 ✓
9.2 EB05 7.0 · IC025 +2.6
3/3 methods agree
Lab value / disease markerserious n=41 · ♀ 0% (drug 60%) · 100% cliniciannot reported in cached trials
Altered state of consciousness6629.5
8.8–10.2ROR 9.5 · calibrated p 0.038 ✓
9.2 EB05 8.6 · IC025 +3.1
3/3 methods agree
Not in label — unassessedage-adj. PRR 6.7 · serious PRR 7.7not reported in cached trials
Parainfluenzae virus infection479.3
7.0–12.5ROR 9.3 · calibrated p 0.045 ✓
8.6 EB05 6.7 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=47 · ♀ 0% (drug 60%) · 100% cliniciannot reported in cached trials
Blood pressure diastolic abnormal769.1
7.2–11.4ROR 9.1 · calibrated p 0.047 ✓
8.6 EB05 7.0 · IC025 +2.7
3/3 methods agree
Lab value / disease markerserious n=76 · 100% cliniciannot reported in cached trials
Neurotoxicity5069.0
8.2–9.8ROR 9.0 · calibrated p 0.046 ✓
8.7 EB05 8.1 · IC025 +3.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 9.2 · serious PRR 7.3 · 100% cliniciannot reported in cached trials
Aplasia588.9
6.9–11.6ROR 8.9 · calibrated p 0.051
8.3 EB05 6.6 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=58 · ♀ 0% (drug 60%) · 100% cliniciannot reported in cached trials
Mixed liver injury848.9
7.1–11.0ROR 8.9 · calibrated p 0.051
8.4 EB05 6.9 · IC025 +2.7
3/3 methods agree
Not in label — unassessedserious n=84 · 100% cliniciannot reported in cached trials
Rhinovirus infection1018.1
6.7–9.9ROR 8.2 · calibrated p 0.065
7.7 EB05 6.5 · IC025 +2.6
3/3 methods agree
Not in label — unassessedserious n=98 · ♀ 38% (drug 60%)not reported in cached trials
Blood pressure systolic abnormal658.0
6.3–10.2ROR 8.0 · calibrated p 0.070
7.5 EB05 6.1 · IC025 +2.5
3/3 methods agree
Lab value / disease markerserious n=65 · ♀ 100% (drug 60%) · 100% cliniciannot reported in cached trials
Dermatitis exfoliative generalised877.7
6.3–9.6ROR 7.8 · calibrated p 0.076
7.3 EB05 6.1 · IC025 +2.5
3/3 methods agree
Not in label — unassessedserious n=87 · ♀ 0% (drug 60%) · 100% cliniciannot reported in cached trials
Herpes zoster (shingles)1,4497.7
7.3–8.1ROR 7.8 · calibrated p 0.071
7.5 EB05 7.2 · IC025 +2.8
3/3 methods agree
Likely indication confounding
term in indications; also in warnings
age-adj. PRR 6.6 · serious PRR 6.8not reported in cached trials

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Neutropenia / agranulocytosis4,4345.45.3–5.6signal
Opportunistic infection2,0674.64.4–4.8signal
Severe cutaneous reaction8803.63.3–3.8signal
Thrombocytopenia2,2683.13.0–3.2signal
Kidney injury3,8592.52.5–2.6signal
Serious infection5,4092.12.1–2.2signal
Anaemia1,9862.01.9–2.1raised
Hyponatraemia4991.91.7–2.0raised
Venous thromboembolism1,3071.81.7–1.9raised
Interstitial lung disease4871.51.4–1.7raised
Arrhythmia / qt9611.51.4–1.6raised
Liver injury1,3571.31.3–1.4raised
Fall / fracture1,5681.21.2–1.3raised
Depression1,1551.21.2–1.3raised
Pancreatitis3111.21.0–1.3raised
Heart failure6601.11.0–1.2raised

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Valacyclovir as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (0 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Fatigue (tiredness)4,3171.7
1.6–1.7ROR 1.7 · calibrated p 0.776
1.7 EB05 1.6 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.6not reported in cached trials
Nausea3,9801.5
1.5–1.6ROR 1.5 · calibrated p 0.670
1.5 EB05 1.5 · IC025 +0.5Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.6NCT00306787: 18/385 (4.7%) on Valacyclovir
Drug ineffective (drug did not work)3,9630.9
0.9–0.9ROR 0.9 · calibrated p 0.240
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.9 · serious PRR 0.9not reported in cached trials
Off label use (used outside approved label)3,8391.3
1.3–1.4ROR 1.3 · calibrated p 0.538
1.3 EB05 1.3 · IC025 +0.4Reporting / coding artifactage-adj. PRR 1.3 · serious PRR 1.6not reported in cached trials
Diarrhoea (diarrhea)3,6481.7
1.6–1.8ROR 1.7 · calibrated p 0.794
1.7 EB05 1.7 · IC025 +0.7Labeled adverse reaction
exact term
age-adj. PRR 1.5 · serious PRR 1.6NCT00306787: 5/385 (1.3%) on Valacyclovir
Headache2,9651.4
1.4–1.5ROR 1.4 · calibrated p 0.601
1.4 EB05 1.4 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.5 · ♀ 80% (drug 60%)NCT00306787: 17/385 (4.4%) on Valacyclovir
Pyrexia (fever)2,7532.4
2.3–2.5ROR 2.4 · calibrated p 0.835
2.4 EB05 2.3 · IC025 +1.2
3/3 methods agree
Labeled adverse reaction
exact term
age-adj. PRR 2.2 · serious PRR 2.3not reported in cached trials
Pain2,7081.3
1.3–1.4ROR 1.3 · calibrated p 0.529
1.3 EB05 1.3 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.4 · serious PRR 1.3NCT00306787: 4/385 (1.0%) on Valacyclovir
Rash2,3221.6
1.5–1.7ROR 1.6 · calibrated p 0.724
1.6 EB05 1.5 · IC025 +0.6Likely indication confounding
term in indications; also in warnings
age-adj. PRR 1.6 · serious PRR 1.6not reported in cached trials
Dizziness2,3091.4
1.3–1.4ROR 1.4 · calibrated p 0.578
1.4 EB05 1.3 · IC025 +0.4Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.3not reported in cached trials
Febrile neutropenia2,17610.1
9.7–10.6ROR 10.4 · calibrated p 0.028 ✓
9.8 EB05 9.5 · IC025 +3.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 10.9 · serious PRR 8.2 · 93% cliniciannot reported in cached trials
Dyspnoea (shortness of breath)2,1281.1
1.1–1.2ROR 1.1 · calibrated p 0.393
1.1 EB05 1.1 · IC025 +0.1Labeled adverse reaction
exact term
age-adj. PRR 1.0 · serious PRR 1.1not reported in cached trials
Vomiting2,0921.3
1.3–1.4ROR 1.3 · calibrated p 0.540
1.3 EB05 1.3 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.3NCT00306787: 3/385 (0.8%) on Valacyclovir
Asthenia (weakness)1,9641.6
1.5–1.6ROR 1.6 · calibrated p 0.695
1.6 EB05 1.5 · IC025 +0.6Not in label — unassessedage-adj. PRR 1.3 · serious PRR 1.4not reported in cached trials

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Valacyclovir ↔ Acute kidney injury.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Valacyclovir?

In FDA FAERS, the most frequently co-reported reaction terms for Valacyclovir are fatigue, nausea, diarrhoea, headache, pyrexia, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Valacyclovir have an FDA boxed warning?

No. The FDA label retrieved for Valacyclovir has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Valacyclovir causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.